Business Context and Reporting Period
Company: iBio, Inc. (formerly iBioPharma, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2010
Business Overview: iBio is a biotechnology company focused on commercializing its proprietary "iBioLaunch" platform, a plant-based technology for producing biologics, vaccines, and therapeutic proteins. The company operates with a lean internal staff, outsourcing research and development (R&D) primarily to the Center for Molecular Biotechnology of Fraunhofer USA, Inc. (FhCMB). Key product candidates include vaccines for H1N1 and H5N1 influenza, anthrax, plague, and HPV. The company discontinued its nutritional supplement business effective April 1, 2009.
Key Financial Metrics
| Metric | Year Ended June 30, 2010 | Year Ended June 30, 2009 |
|---|---|---|
| Revenue (Sales) | $0 | $1,176,604 |
| Net Loss | $(6,078,020) | $(1,907,296) |
| Operating Loss | $(4,587,339) | $(1,926,192) |
| Research & Development Expenses | $2,517,360 | $797,400 |
| General & Administrative Expenses | $2,069,979 | $1,804,561 |
| Cash and Cash Equivalents (End of Period) | $909,932 | $1,039,244 |
| Working Capital | $(2,829,000) (Deficiency) | Not explicitly stated (Positive Equity) |
| Accumulated Deficit | $(13,519,492) | $(8,684,868) |
| Derivative Instrument Liability | $1,714,084 | $0 |
Note: The 2010 net loss includes a non-cash expense of approximately $1.51 million related to the change in fair value of derivative instrument liabilities (warrants) due to the adoption of ASC 815-40.
Material Changes vs. Prior Period
- Cessation of Product Sales: Revenue dropped to zero in 2010 compared to $1.18 million in 2009. This is due to the discontinuance of the nutritional supplement business on April 1, 2009, and the conclusion of an advisory service project with FhCMB.
- Increased R&D Spend: R&D expenses increased by 216% (from $797k to $2.52M), primarily driven by a $1.75 million increase in services provided by FhCMB and costs associated with preparing an Investigational New Drug (IND) application.
- Derivative Liability Impact: A significant non-cash expense of $1.51 million was recorded in 2010 due to the reclassification of warrants issued in 2008 as derivative liabilities. This was driven by an increase in the company's stock price and volatility.
- Liquidity Position: Cash decreased by $129,000. The company moved from a positive working capital position in 2009 to a working capital deficiency of $2.83 million in 2010, largely due to the recognition of the derivative liability.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The independent auditors have issued a "going concern" opinion. The company has incurred significant losses and negative cash flows. Management states that current cash resources are expected to support operations only through the balance of calendar 2010. Additional financing is required to continue operations.
- Outlook: The company plans to fund future activities through licensing arrangements and/or the sale of equity securities. A Phase 1 human clinical trial for an influenza vaccine candidate is scheduled to begin in late 2010.
- Contractual Obligations: The company has significant commitments to FhCMB totaling $11.8 million over the next several years, including $3.2 million due within one year. This includes $1.1 million currently recorded in accounts payable.
- Internal Control Weakness: A material weakness in internal control over financial reporting was identified regarding non-routine, complex transactions, which required a restatement of prior financial statements. Management has taken steps to remediate this.
- Risks: Key risks include the inability to raise additional capital, failure of clinical trials, dependence on FhCMB for R&D, and the volatility of the derivative liability which impacts reported net loss.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure equity financing before the end of calendar 2010 to avoid ceasing operations.
- Derivative Liability: Monitor the fair value of the warrant liability, as fluctuations in stock price will continue to create significant non-cash volatility in the net loss.
- FhCMB Relationship: Assess the status of the $11.8 million commitment to FhCMB and the company's ability to meet the $3.2 million due within one year.
- Clinical Trial Progress: Confirm the initiation and results of the Phase 1 clinical trial for the influenza vaccine candidate scheduled for late 2010.
- Internal Controls: Review subsequent filings to confirm the remediation of the material weakness in internal controls over financial reporting.